Biosimilar Antibodies & Proteins
In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on biosimilar antibodies and proteins. The range of products covers industry data as well as in-depth strategic assessment and analysis of biosimilar antibody and protein companies, R&D pipeline, and sales and market information.
In fact, in a comparative study of over 100,000 pregnancies with zofran or without, the difference in the number of stillbirths was very slight and clinically irrelevant. The product works best on the areas where the skin is damaged, which idealistically means that the medicine is most effective when used on the face, upper back and shoulders. Neurontin (generic brand neurontin, generic neurontin, generic.
Dapoxetine is a well established and fda approved drug. The drugs & alcohol program offers addiction treatment, counseling, addiction medication and group https://oldtownwhiskeyclub.com/previous-events/ meetings with professional counselors. In some states, such as texas, there are laws that make this kind of driving illegal, and the state.
Subscribe to
our newsletters!
Showing all 13 results
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Prolia & Xgeva (denosumab).€ 300.00
- July of 2023This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Humira (adalimumab).€ 400.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Soliris (eculizumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar or biosuperior antibodies of Xolair (omalizumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Lucentis (ranibizumab)€ 300.00
- On the same day of purchaseThis product provides basic information on drug candidates in R&D as biosimilar antibodies of Eylea (aflibercept)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Stelara (ustekinumab).€ 300.00
- March of 2023Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
- February of 2023Antibody Target, Technology & Pipeline Database€ 1600.00
- March of 2022This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2021€ 100.00
- December of 2019Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00
- February of 2019This report provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.€ 100.00